<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-5547-21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TYSABRI 300 MG/15ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NATALIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5558.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="VETTER PHARMA-FERTIGUNG, GMBH &amp; CO. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            VETTER PHARMA-FERTIGUNG, GMBH & CO. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Biogen Idec B.V-Natherland
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tysabri is used to treat multiple sclerosis (MS).&nbsp; It contains the active substance natalizumab. This is called a monoclonal antibody.</p><p>&nbsp;</p><p>MS causes inflammation in the brain that damages the nerve cells. This inflammation happens when white blood cells get into the brain and spinal cord. This medicine stops the white blood cells getting through to the brain. This reduces nerve damage caused by MS.</p><p>&nbsp;</p><p><strong>Symptoms</strong> <strong>of multiple sclerosis</strong></p><p>The symptoms of MS vary from patient to patient, and you may experience some or none of them.</p><p>&nbsp;</p><p><strong>They may include:</strong> walking problems, numbness in the face, arms or legs; problems with vision; tiredness; feeling off-balance or light headed; bladder and bowel problems; difficulty in thinking and concentrating; depression; acute or chronic pain; sexual problems; stiffness and muscle spasms.</p><p>When the symptoms flare up, it is called a <em>relapse</em> (also known as an exacerbation or an attack). When a relapse occurs, you may notice the symptoms suddenly, within a few hours, or slowly progressing over several days. Your symptoms will then usually improve gradually (this is called a remission).</p><p>&nbsp;</p><p><strong>How Ty</strong><strong>sabri can help</strong></p><p>In trials, this medicine approximately halved the build-up of disability caused by MS, and decreased the number of MS attacks by about two-thirds. While you are treated with &nbsp;this medicine you might not notice any improvement, but it may still be working to prevent your MS becoming worse.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before you start treatment with this medicine, it is important that you and your doctor have discussed the benefits you could expect to receive from this treatment and the risks that are associated with it.</p><p>&nbsp;</p><p><strong>You must not be given Tysabri </strong></p><p>&middot;&nbsp;&nbsp; If you are <strong>allergic</strong> to natalizumab or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; If you have been <strong>diagnosed with PML</strong> (<em>progressive multifocal leukoencephalopathy</em>). PML is an uncommon infection of the brain.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; If your <strong>immune system</strong> has a<strong> </strong>serious problem. This may be due to disease (such as HIV), or to a medicine you are taking, or have taken in the past (see below).</p><p><s>&nbsp;</s></p><p>&middot;&nbsp;&nbsp; If you are taking <strong>medicines that affect your immune system,</strong> including certain other medicines used to treat MS. These medicines cannot be used with Tysabri.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; If you <strong>have</strong> <strong>cancer </strong>(unless it is a type of skin cancer called <em>basal cell carcinoma</em>).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p><strong>You need to discuss with your doctor </strong>whether Tysabri is the most suitable treatment for you. Do this before you start taking Tysabri, and when you have been receiving Tysabri for more than two years.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Possible brain infection (PML)</strong></p><p><strong>&nbsp;</strong></p><p>Some people receiving this medicine (fewer than 1 in 100) have had an uncommon brain infection called PML (<em>progressive multifocal leukoencephalopathy</em>). PML can lead to severe disability or death.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Before starting treatment, <strong>all patients will have blood tests </strong>arranged by the doctor for JC virus infection. JC virus is a common virus that does not normally make you ill. However, PML is linked to an increase of JC virus in the brain. The reason for this increase in some patients treated with Tysabri is not clear. Before and during treatment, your doctor will test your blood to check if you have antibodies to the JC virus, which are a sign that you have been infected by the JC virus.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp; Your doctor will arrange a <strong>Magnetic Resonance Imaging (MRI) scan</strong>, which will be repeated during treatment to rule out PML.<br />&nbsp;</p><p>&middot;&nbsp;&nbsp; <strong>The symptoms of PML</strong> may be similar to an MS relapse (see section 4, <em>Possible side effects</em>). You can also get PML up to 6 months after stopping Tysabri treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor as soon as possible</strong> if you notice your MS getting worse, if you notice any new symptoms while you are on Tysabri treatment or for up to 6 months afterwards.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <strong>Tell your partner or caregivers</strong> about what to look out for (see also section 4, <em>Possible side effects</em>). Some symptoms might be difficult to spot by yourself, such as changes in mood or behaviour, confusion, speech and communication difficulties. If you get any of these, <strong>you</strong><strong> may need further tests</strong>. Keep looking out for symptoms in the 6 months after stopping &nbsp;Tysabri.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Keep the patient alert card you have been given by your doctor. It includes this information. Show it to your partner or caregivers.</p><p><strong>&nbsp;</strong></p><p><strong>Three things can increase your risk of PML </strong>with Tysabri.<strong> </strong>If you have two or more of these risk factors, the risk is increased further:<strong> </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <strong>If you have antibodies to the JC virus </strong>in your blood. These are a sign that the virus is in your body. You will be tested before and during Tysabri treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <strong>If</strong><strong> you are treated for a long time </strong>with Tysabri, especially if it is more than two years.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <strong>If you have</strong> <strong>taken a medicine called an <em>immunosuppressant</em></strong>, that reduces the activity of your immune system.</p><p><strong>&nbsp;</strong></p><p><strong>Another condition,</strong> called JCV GCN (<em>JC virus granule cell neuronopathy</em>), is also caused by JC virus and has occurred in some patients receiving Tysabri. The symptoms of JCV GNC are similar to PML.</p><p>&nbsp;</p><p><strong>For those with a lower risk of PML,</strong> your doctor may repeat the test regularly to check that:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; You still do not have antibodies to the JC virus in your blood.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; If you have been treated for more than 2 years, you still have a lower level of JC virus antibodies in your blood.</p><p><strong>&nbsp;</strong></p><p><strong>If someone gets PML </strong></p><p>PML can be treated, and Tysabri treatment will be stopped. However, some people get a reaction as Tysabri is removed from the body. This reaction (known as IRIS or immune reconstitution inflammatory syndrome) may lead to your condition getting worse, including worsening of brain function.</p><p>&nbsp;</p><p><strong>Look out for other infections</strong></p><p>Some infections other than PML may also be serious and can be due to viruses, bacteria, and other causes.</p><p>&nbsp;</p><p><strong>Tell a doctor or nurse immediately</strong> if you think you have an infection (see also section 4, <em>Possible side effects</em>).</p><p>&nbsp;</p><p><strong>Changes in blood platelets</strong></p><p>Natalizumab may reduce platelets in the blood which are responsible for clotting. This may result in a condition called thrombocytopenia (see section 4) in which your blood may not clot quickly enough to stop bleeding. This can lead to bruising as well as other more serious problems such as excessive bleeding. You should talk to your doctor immediately if you have unexplained bruising, red or purple spots on the skin (called petechiae), bleeding from skin cuts that does not stop or oozes, prolonged bleeding from the gums or nose, blood in urine or stools, or bleeding in the whites of your eyes.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children or adolescents under the age of 18 years.</p><p>&nbsp;</p><p><strong>Other medicines and Tysabri</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; You <strong>must not</strong> be given this medicine if you are now being treated with medicines that affect your <strong>immune system</strong>, including certain other medicines to treat your MS.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; You might not be able to use this medicine if you have <strong>previously</strong> had any medicines that affect your immune system.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <strong>Do not use this medicine if you are pregnant, </strong>unless you have discussed this with your doctor. Be sure to tell your doctor immediately if you get pregnant, think you may be pregnant, or if you are planning to become pregnant.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <strong>Do not breast‑feed whilst using Tysabri.</strong> Your doctor will help you decide whether you should choose to stop breast‑feeding &nbsp;or stop using the medicine.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. The risk to the baby and benefit to the mother will be taken into consideration by your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Dizziness is a very common side effect. If you are affected, do not drive or use machines.</p><p>&nbsp;</p><p><strong>Tysabri</strong><strong> contains sodium</strong></p><p>Each vial of this medicine contains 2.3 mmol (or 52 mg) of sodium. After dilution for use, this medicinal product contains 17.7&nbsp;mmol (or 406&nbsp;mg) sodium per dose. This should be considered if you are on a controlled sodium diet.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tysabri IV infusion will be given to you by a doctor experienced in the treatment of MS. Your doctor may switch you directly from another medicine for MS to Tysabri if there are no problems caused by your previous treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Your doctor will order <strong>blood tests</strong> for antibodies to the JC virus and other possible problems.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Your doctor will arrange an <strong>MRI scan</strong>, which will be repeated during treatment.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <strong>To switch from some MS medicines,</strong> your doctor may advise you to wait for a certain time to ensure that most of the previous medicine has left your body.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; For adults the recommended dose is 300&nbsp;mg, given once every 4&nbsp;weeks.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Tysabri must be diluted before it is given to you. It is given as a drip into a vein (by intravenous infusion), usually in your arm. This takes about 1&nbsp;hour.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Information for medical or healthcare professionals on how to prepare and administer the medicine is provided at the end of this leaflet.</p><p>&nbsp;</p><p><strong>If you stop using Tysabri</strong></p><p>Regular dosing with Tysabri is important, especially in the first few months of treatment. It is important to continue with your medicine for as long as you and your doctor decide that it is helping you. Patients who received one or two doses of Tysabri, and then had a gap in treatment of three months or more, were more likely to have an allergic reaction when restarting treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Checking for allergic reactions</strong></p><p>A few patients have had an allergic reaction to this medicine. Your doctor may check for allergic reactions during the infusion and for 1&nbsp;hour afterwards. See also section 4, <em>Possible side effects</em>.</p><p>&nbsp;</p><p><strong>If you miss your dose of Tysabri</strong></p><p>If you miss your usual dose of Tysabri, arrange with your doctor to receive it as soon as you can. You can then continue to receive your dose of Tysabri every 4&nbsp;weeks.</p><p>&nbsp;</p><p><strong>Will Tysabri always work?</strong></p><p>In a few patients receiving Tysabri, the body&rsquo;s natural defences may stop the medicine from working properly over time, as the body develops antibodies to the medicine. Your doctor can decide whether this medicine is not working properly for you from blood tests and will stop the treatment, if necessary.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you have any further questions on Tysabri, ask your doctor. Always use this medicine exactly as described in this leaflet or as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Speak to your doctor or nurse immediately </strong>if you notice any of the following.</p><p><strong>&nbsp;</strong></p><p><strong>Signs of a brain infection</strong></p><p>&middot;&nbsp;&nbsp; Changes in personality and behaviour such as confusion, delirium or loss of consciousness,</p><p>&middot;&nbsp;&nbsp; Seizures (fits)</p><p>&middot;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp; Nausea / vomiting</p><p>&middot;&nbsp;&nbsp; Stiff neck</p><p>&middot;&nbsp;&nbsp; Extreme sensitivity to bright light</p><p>&middot;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp; Rash (anywhere on the body)</p><p>&nbsp;</p><p>These symptoms may be caused by an infection of the brain (<em>encephalitis or PML</em>) or its covering layer (<em>meningitis</em>).</p><p>&nbsp;</p><p><strong>Signs of other serious infections</strong></p><p>&middot;&nbsp;&nbsp; An unexplained fever</p><p>&middot;&nbsp;&nbsp; Severe diarrhoea</p><p>&middot;&nbsp;&nbsp; Shortness of breath</p><p>&middot;&nbsp;&nbsp; Prolonged dizziness</p><p>&middot;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp; Weight loss</p><p>&middot;&nbsp;&nbsp; Listlessness</p><p>&middot;&nbsp;&nbsp; Impaired vision</p><p>&middot;&nbsp;&nbsp; Pain or redness of the eye(s)</p><p>&nbsp;</p><p><strong>Signs of an allergic reaction</strong></p><p>&middot;&nbsp;&nbsp; Itchy rash (<em>hives</em>)</p><p>&middot;&nbsp;&nbsp; Swelling of your face, lips or tongue</p><p>&middot;&nbsp;&nbsp; Difficulty breathing</p><p>&middot;&nbsp;&nbsp; Chest pain or discomfort</p><p>&middot;&nbsp;&nbsp; Increase or decrease in your blood pressure (your doctor or nurse will notice this if they are monitoring your blood pressure)</p><p>&nbsp;</p><p>These are most likely during or shortly after the infusion.</p><p>&nbsp;</p><p><strong>Signs of a possible liver problem</strong></p><p>&middot;&nbsp;&nbsp; Yellowing of your skin or the whites of your eyes</p><p>&middot;&nbsp;&nbsp; Unusual darkening of the urine</p><p>&middot;&nbsp;&nbsp; Abnormal liver function test</p><p>&nbsp;</p><p><strong>Speak to a doctor or nurse immediately </strong>if you get any of the side effects listed above, or if you think you have an infection. <strong>Show</strong> <strong>your patient alert card</strong> and this package leaflet to any doctor or nurse who treats you, not only to your neurologist.</p><p><strong>&nbsp;</strong></p><p><strong>Other side effects</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp; Urinary tract infection</p><p>&middot;&nbsp;&nbsp; Sore throat and runny or blocked up nose</p><p>&middot;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp; Feeling sick (<em>nausea</em>)</p><p>&middot;&nbsp;&nbsp; Joint pain</p><p>&middot;&nbsp;&nbsp; Tiredness</p><p>&middot;&nbsp;&nbsp; Dizziness, feeling sick (<em>nausea</em>), itching and chills during or shortly after infusion</p><p><strong>&nbsp;</strong></p><p><strong>Common </strong>&nbsp;(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp; Anaemia (decrease in your red blood cells which can make your skin pale and can make you feel breathless or lacking energy)</p><p>&middot;&nbsp;&nbsp; Allergy (<em>hypersensitivity</em>)</p><p>&middot;&nbsp;&nbsp; Shivering</p><p>&middot;&nbsp;&nbsp; Itchy rash (<em>hives</em>)</p><p>&middot;&nbsp;&nbsp; Being sick (<em>vomiting</em>)</p><p>&middot;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp; Difficulty breathing (<em>dyspnoea)</em></p><p>&middot;&nbsp;&nbsp; Reddening of the face or body (<em>flushing</em>)</p><p>&middot;&nbsp;&nbsp; Herpes infections</p><p>&middot;&nbsp;&nbsp; Discomfort around the place you have had your infusion.&nbsp; You could experience bruising, redness, pain, itching or swelling</p><p>&nbsp;</p><p><strong>Uncommon </strong>&nbsp;(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp; Severe allergy (<em>anaphylactic reaction</em>)</p><p>&middot;&nbsp;&nbsp; Progressive multifocal leukoencephalopathy (PML)</p><p>&middot;&nbsp;&nbsp; Inflammatory disorder after discontinuation of the medicinal product</p><p>&middot;&nbsp;&nbsp; Facial swelling</p><p>&middot;&nbsp;&nbsp; An increase in the number of white blood cells (<em>eosinophilia</em>)</p><p>&middot;&nbsp;&nbsp; Reduction in blood platelets</p><p>&middot;&nbsp;&nbsp; Easy bruising (purpura)</p><p><strong>&nbsp;</strong></p><p><strong>Rare </strong>&nbsp;(may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp; Herpes infection in the eye</p><p>&middot;&nbsp;&nbsp; Severe anaemia (decrease in your red blood cells which can make your skin pale and can make you feel breathless or lacking energy).</p><p>&middot;&nbsp;&nbsp; Severe swelling under the skin</p><p>&middot;&nbsp;&nbsp; High levels of bilirubin in the blood (<em>hyperbilirubinaemia</em>) which may cause symptoms such as yellowing of your eyes or skin, fever and tiredness</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data)</p><ul><li>Unusual infections (so-called &ldquo;<em>opportunistic infections</em>&rdquo;)</li><li>Damage to your liver</li></ul><p><em>&nbsp;</em></p><p><strong>Speak to your doctor as soon as possible</strong> if you think you have an infection<em>.</em></p><p>You will also find this information in the patient alert card you have been given by your doctor.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in section 6 of this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report</strong> <strong>any</strong> <strong>side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date stated on the label and carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p><strong>Unopened vial:</strong></p><p>Store in a refrigerator (2&deg;C&nbsp;to&nbsp;8&deg;C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p><strong>Diluted solution:</strong></p><p>After dilution, immediate use is recommended. If not used immediately, the diluted solution must be stored at 2˚C&nbsp;to 8˚C and infused within 8&nbsp;hours of dilution.</p><p>&nbsp;</p><p>Do not use this medicine if you notice particles in the liquid and/or the liquid in the vial is discoloured.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is natalizumab. Each 15&nbsp;mL vial of concentrate contains 300&nbsp;mg natalizumab (20&nbsp;mg per mL). When diluted, the solution for infusion contains approximately 2.6 mg per mL of natalizumab.</p><p><u>&nbsp;</u></p><p>The other ingredients are:</p><p>Sodium phosphate, monobasic, monohydrate,</p><p>Sodium phosphate, dibasic, heptahydrate,</p><p>Sodium chloride (see section 2 &lsquo;Tysabri contains sodium&rsquo;),</p><p>Polysorbate 80 (E 433)</p><p>Water for injections<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Tysabri is a clear, colourless to slightly cloudy liquid. 
	Each carton contains one glass vial.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Final batch Releaser</strong><br />Biogen Netherlands B.V.</p><p>Prins Mauritslaan 13</p><p>1171 LP Badhoevedorp</p><p>The Netherlands</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer</strong></p><p>Vetter Pharma-Fertigung GmbH &amp; Co. KG</p><p>Mooswiesen 2, 88214 Ravensburg</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                  05/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُستخدم دواء تيسابري &nbsp;Tysabriلعلاج مرض التصلب المتعدد &nbsp;(MS) فالدواء يحتوي على المادة الفعالة )ناتاليزوماب،(natalizumab &nbsp;والتي يُطلق عليها اسم الجسم المضاد وحيد النسيلة.</p><p dir="RTL">يسبب التصلب المتعدد MS التهاب في المخ &nbsp;مما يؤدي إلى إتلاف خلايا الأعصاب، ويحدث هذا الالتهاب عندما تدخل خلايا الدم البيضاء إلى المخ والحبل الشوكي، فهذا الدواء يمنع خلايا الدم البيضاء من الوصول إلى المخ. وهذا يقلل من تلف الأعصاب الناتج عن مرض التصلب المتعدد MS.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>مرض</strong><strong> </strong><strong>التصلب</strong><strong> </strong><strong>المتعدد</strong></p><p dir="RTL">تختلف أعراض مرض التصلب المتعدد من مريض لآخر، فمن الممكن أن تواجه بعض هذه الأعراض ومن الممكن ألا تتعرض لأيِّ منها على الإطلاق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وقد</strong><strong> </strong><strong>تشمل</strong><strong>:</strong><strong> </strong>مشاكل أثناء المشي، الشعور بالتخدر في الوجه، أو الذراعين أو الأرجل، مشاكل في رؤية الأشياء، التعب، الشعور بفقدان التوازن أو الشعور بالدوار، مشاكل في المثانة والأمعاء، صعوبة في التفكير والتركيز، الاكتئاب، ألم حاد أو مزمن، مشاكل جنسية، تيبس وتشنجات العضلات.</p><p dir="RTL">عندما تزداد حدة الأعراض يسمى هذا بالانتكاسة (وتعرف أيضاً باسم تفاقم الحالة أو أزمة حادة). وعند حدوث الانتكاسة، ربما تلاحظ الأعراض فجأة خلال ساعات قليلة أو تزداد ببطء خلال عدة أيام .وعندئذ سوف تتحسن الأعراض تدريجيًا) وهذا ما يسمى بخمود حدة المرض.(</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يمكن أن يساعد تيسابري </strong><strong>Tysabri</strong><strong> </strong></p><p dir="RTL">في التجارب<strong> </strong>استطاع هذا الدواء أن يقلل من الإعاقة المتراكمة التي يسببها مرض التصلب المتعدد MS بمقدار النصف تقريبَّا كما أدى أيضًا إلى تخفيض عدد الانتكاسات الحادة للمرض بنحو الثلثين. أثناء العلاج باستخدام هذا الدواء ربما لا تشعر بأيِّ تحسن ولكن ربما يستمر الدواء في العمل على منع ازدياد تفاقم الحالة المرضية الناتجة عن مرض التصلب المتعدد.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قبل أن تبدأ العلاج باستعمال هذا الدواء من الضروري أن تناقش أنت وطبيبك المزايا التي يمكن أن تتوقع الحصول عليها من هذا العلاج والمخاطر المرتبطة باستعمال هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا</strong><strong> </strong><strong>يجب أن يتم إعطاؤك</strong><strong> </strong><strong>تيسابري </strong><strong>Tysabri</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كان لديك حساسية ضد ناتاليزوماب أو أي من المكونات الأخرى في هذا الدواء (مذكورة في القسم ٦).</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا تم تشخيص إصابتك بمرض الالتهاب المتقدم المتعدد البؤرات لمادة المخ البيضاء PML وهو التهاب غير شائع يصيب المخ.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كانت لديك مشكلة خطيرة في جهازك المناعي قد يكون هذا بسبب مرض مثل ) فيروس نقص المناعة &nbsp;HIV) أو نتيجة لدواء تتناوله حاليا أو تناولته من قبل (أنظر أدناه(.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تتناول أدوية تؤثر على جهازك المناعي بما في ذلك بعض الأدوية الأخرى التي تُستخدم لعلاج مرض التصلب المتعدد MS . هذه الأدوية لا يمكن استخدامها مع تيسابري .Tysabri</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت مصابًا بمرض السرطان )ما لم يكن من نوع سرطان الجلد المسمى باسم سرطان <em>كارسينوما الخلايا الأساسية</em>(.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات </strong></p><p dir="RTL"><strong>يجب عليك أن تتناقش مع طبيبك</strong> فيما إذا كان تيسابري Tysabri هو العلاج الأنسب لك. افعل ذلك قبل أن تبدأ بتناول تيسابري Tysabri، وإذا ما كنت تتلقى تيسابري Tysabri منذ أكثر من عامين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>احتمالية الإصابة بالتهاب في المخ (</strong><strong>PML</strong><strong>)</strong></p><p dir="RTL">يعاني بعض الأشخاص الذين يتلقون هذا الدواء (أقل من 1 بين كل 100) من التهاب في المخ غير شائع يسمى PML (<em>الالتهاب</em><em> </em><em>المتقدم</em><em> </em><em>المتعدد</em><em> </em><em>البؤرات</em><em> </em><em>لمادة المخ البيضاء</em>). ويمكن أن تؤدي الإصابة بـ PML إلى حدوث إعاقة شديدة أو الوفاة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل بدء العلاج، سوف <strong>يخضع جميع المرضى لفحوصات دم</strong> يقوم الطبيب بالترتيب لإجرائها من أجل التحقق من وجود عدوى فيروس JC. فيروس JC هو فيروس شائع وعادةً لا يجعلك مريضًا. ومع ذلك، ترتبط الإصابة بمرض PML بزيادة في فيروس JC في المخ. والسبب وراء هذه الزيادة لدى بعض المرضى الذين عولجوا باستخدام تيسابري Tysabri غير واضح. وسوف يقوم الطبيب قبل وأثناء العلاج بفحص دمك للتحقق مما إذا كانت لديك أجسام مضادة لفيروس JC، وهي علامة على إصابتك بفيروس JC.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يقوم طبيبك بالترتيب لإجراء فحص <strong>التصوير بالرنين المغناطيسي (</strong><strong>MRI</strong><strong>)</strong>، والذي سيتكرر أثناء العلاج لاستبعاد الإصابة بمرض PML.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قد تكون أعراض الإصابة بمرض </strong><strong>PML</strong> مشابهة للإصابة بانتكاس مرض التصلب العصبي المتعدد (انظر القسم 4، <em>الآثار الجانبية المحتملة</em>). يمكنك أيضًا أن تصاب بمرض PML حتى 6 أشهر بعد إيقاف العلاج باستخدام تيسابري &nbsp;Tysabri.</p><p dir="RTL"><strong>أخبر طبيبك</strong> <strong>في أقرب وقت ممكن</strong> إذا لاحظت أن إصابتك بالتصلب العصبي المتعدد تتفاقم، أو إذا لاحظت أي أعراض جديدة أثناء العلاج باستخدام تيسابري Tysabri أو لمدة تصل إلى 6 أشهر بعد ذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تحدث </strong><strong>إلى</strong><strong> </strong><strong>شريك</strong><strong> </strong><strong>حياتك</strong><strong> </strong><strong>أو</strong> <strong>من</strong> <strong>يُقدِّم</strong><strong> </strong><strong>لك</strong><strong> </strong><strong>الرعاية</strong> حول ما يجب أن ينتبه إليه (انظر أيضًا القسم 4، الآثار الجانبية<em> المحتملة</em>). قد يكون من الصعب تحديد بعض الأعراض بنفسك مثل التغيرات في المزاج أو السلوك والارتباك والصعوبة في التكلم والتواصل، إذا تعرضت لظهور أي من هذه الأعراض، فقد <strong>تحتاج إلى مزيد من الفحوصات</strong>. استمر في مراقبة ظهور أي أعراض في غضون 6 أشهر بعد إيقاف تيسابري Tysabri.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ ببطاقة تنبيه المريض التي أعطاها لك طبيبك، فهي تتضمن هذه المعلومات. أعطِها لشريكك أو مقدمي الرعاية للاطلاع عليها.</p><p dir="RTL"><strong>هناك ثلاثة أشياء يمكن أن تزيد من خطر إصابتك بمرض </strong><strong>PML</strong> مع العلاج باستخدام تيسابري Tysabri. إذا كان لديك عاملين أو أكثر من عوامل الخطر هذه، فسوف تزداد المخاطر بشكل أكبر:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان</strong><strong>ت</strong><strong> لديك أجسام مضادة لفيروس </strong><strong>JC</strong> في دمك. هذه علامة على وجود الفيروس في جسمك. سيتم فحصك قبل وأثناء العلاج باستخدام تيسابري Tysabri.</p><p dir="RTL"><strong>إذا تم علاجك لفترة طويلة</strong> باستخدام تيسابري Tysabri، خاصة إذا كانت فترة العلاج أكثر من عامين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا</strong><strong> </strong><strong>كنت </strong><strong>قد تناولت دواءً يسمى <em>مثبطًا للمناعة</em></strong>، فإن ذلك يقلل من نشاط جهاز المناعة لديك.</p><p dir="RTL"><strong>هناك حالة أخرى</strong>، تسمى JCV GCN (<em>اعتلال الخلايا العصبية لطبقة الخلايا الحبيبية لفيروس </em><em>JC</em>)، يسببها أيضًا فيروس JC وقد حدثت لدى بعض المرضى الذين يتلقون تيسابري Tysabri. أعراض الإصابة بـ JCV GNC مشابهة لأعراض الإصابة بمرض PML</p><p dir="RTL">بالنسبة <strong>لهؤلاء المرضى الذين لديهم خطر الإصابة بمرض </strong><strong>PML</strong><strong> بنسبة أقل</strong>، قد يكرر طبيبك إجراء الفحص الخاص بك بانتظام للتحقق اذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما زالت لا توجد أجسام مضادة لفيروس JC في دمك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم علاجك لفترة أكثر من عامين، فلا يزال لديك مستوى أقل من الأجسام المضادة لفيروس JC في دمك.</p><p dir="RTL"><strong>إذا اصيب أي شخص بمرض </strong><strong>PML</strong></p><p dir="RTL">يمكن علاج مرض PML، وسيتم إيقاف علاج تيسابري Tysabri. ومع ذلك، فإن بعض الناس يظهر لديهم رد فعل بينما تزول أثار تيسابريTysabri &nbsp;من الجسم. قد يؤدي رد الفعل هذا (المعروف باسم IRIS أو متلازمة&nbsp;استنشاء المناعة الالتهابية) إلى تفاقم حالتك، بما في ذلك تدهور وظائف المخ.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>انتبه من الإصابة بالتهابات أخرى</strong></p><p dir="RTL">قد تكون بعض أنواع الالتهابات الأخرى غير PML خطيرة أيضًا، ويمكن أن تكون ناجمة عن فيروسات وبكتيريا وأسباب أخرى.</p><p dir="RTL"><strong>أخبر الطبيب أو الممرضة على الفور</strong> إذا كنت تعتقد أنك مصاب بالتهاب (انظر أيضًا القسم 4، <em>الآثار الجانبية المحتملة</em>).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تغيرات في الصفائح الدموية</strong></p><p dir="RTL">قد يقلل ناتاليزوماب natalizumab من عدد الصفائح الدموية المسؤولة عن التخثر في الدم. وقد يؤدي هذا إلى حالة تسمى قلة الصفيحات (انظر القسم 4) حيث انه قد لا يتجلط دمك بسرعة كافية لوقف النزيف. هذا يمكن أن يؤدي إلى كدمات بالإضافة إلى مشاكل أخرى أكثر خطورة مثل النزيف المفرط. يجب أن تتحدث مع طبيبك على الفور إذا كانت لديك إصابات ليس لها سبب واضح: كدمات، بقع حمراء أو أرجوانية على الجلد (تسمى نمشات)، نزيف من جروح الجلد التي لا تتوقف أو تنضح، نزيف لمدة طويلة من اللثة أو الأنف، دم في البول أو البراز، أو ينزف في بياض عينيك.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا تعطِ هذا<strong> </strong><strong>الدواء </strong>للأطفال أو المراهقين الذين تقل أعمارهم عن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى و</strong><strong>تيسابري </strong><strong>&nbsp;</strong><strong>Tysabri </strong></p><p dir="RTL">أبلغ طبيبك إذا كنت تتناول أو تناولت مؤخراً أو من الممكن أن تتناول أي أدوية أخرى</p><p dir="RTL">&middot;&nbsp; <strong>يجب</strong> عدم إعطائك هذا الدواء إذا كنت تُعالج الآن بأدوية تؤثر على <strong>جهازك المناعي</strong>، بما في ذلك بعض الأدوية الأخرى التي تعالج مرض التصلب المتعدد &nbsp;.MS</p><p dir="RTL">&middot;&nbsp;&nbsp; قد لا تستطيع استخدام هذا الدواء إذا كان <strong>قد سبق</strong> لك استخدام أدوية تؤثر على جهازك المناعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>هذا </strong><strong>الدواء</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنتِ</strong><strong> </strong><strong>حاملاً</strong> ما لم تناقشي هذا الأمر مع طبيبك. وتأكدي من إبلاغ طبيبك فوراً إذا اصبحت حاملاً أو تعتقدين أنك حاملاً أو إذا كنت تخططين لحدوث حمل.&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يجب</strong><strong> </strong><strong>ألا</strong><strong> </strong><strong>تقومي</strong><strong> </strong><strong>بإرضاع</strong><strong> </strong><strong>طفلك</strong><strong> </strong><strong>أثناء</strong><strong> </strong><strong>استعمال </strong><strong>دواء </strong><strong>تيسابري</strong><strong> </strong><strong>Tysabri</strong> وسوف يساعدك طبيبك في اتخاذ القرار بشأن ما إذا كان يجب عليك اختيار التوقف عن إرضاع طفلك &nbsp;بالثدي أو التوقف عن استعمال الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملاً أو تقومين بالرضاعة الطبيعية، أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، اسألي طبيبك للحصول على المشورة قبل تناول هذا الدواء. سيأخذ طبيبك في الاعتبار المخاطر التي يتعرض لها الطفل والفائدة التي تعود على الأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستعمال الماكينات</strong></p><p dir="RTL">تعتبر الدوخة من الآثار الجانبية الشائعة جدًا، إذا كنت متأثرًا بها؛ فلا تقود السيارة أو تشغّل الماكينات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>تيسابري</strong> <strong>Tysabri</strong><strong> على</strong><strong> </strong><strong>الصوديوم</strong></p><p dir="RTL">تحتوي كل قنينة من هذا الدواء على 2.3 ملليمول (أو 52 مللغرام) من الصوديوم. وبعد التخفيف للاستخدام سوف يحتوي هذا المنتج الطبي على 17.7 ملليمول (أو 406 مللغرام) من الصوديوم لكل جرعة. يجب أن يؤخذ هذا بعين الاعتبار من قِبل</p><p dir="RTL">المرضى الذين يتبعون نظامًا غذائيًا منخفض الصوديوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف يقوم طبيب اختصاصي ولديه خبرة في علاج مرض التصلب العصبي المتعدد MS بإعطائك دواء تيسابري Tysabri بالحقن الوريدي. يمكن لطبيبك أن يستبدل لك دواء آخر لمرض التصلب المتعدد ويعطيك تيسابري Tysabri في حال لم تظهر أيُّ مشكلات ناتجة عن علاجك السابق.</p><p dir="RTL">&middot; سوف يطلب طبيبك القيام <strong>بفحوصات</strong><strong> الدم</strong> لاكتشاف الأجسام المضادة لفيروس JC والمشاكل المحتملة الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بالترتيب لإجراء فحص <strong>بالرنين المغناطيسي</strong>، وسوف يتكرر هذا الفحص أثناء فترة العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong>للتحويل</strong><strong> من بعض أدوية المرض التصلب المتعدد</strong>، قد ينصح طبيبك بالانتظار لمدة معينة للتأكد من أن معظم أدويتك السابقة قد زالت آثارها من جسمك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للبالغين، فإن الجرعة الموصى بها 300 &nbsp;مللغرام حيث يتم إعطاؤها مرة واحدة كل 4 أسابيع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تخفيف دواء تيسابري Tysabri قبل إعطائه لك. ويتم إعطاؤه قطرة بقطرة في الوريد (عن طريق التسريب الوريدي) عادة في ذراعك. ويستغرق ذلك مدة حوالي ساعة واحدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي هذه النشرة في القسم الأخير منها على معلومات للأطباء ومتخصصو الرعاية الصحية حول كيفية إعداد وإعطاء الدواء.&nbsp; &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام تيسابري </strong><strong>Tysabri</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعتبر تناول الجرعات المنتظمة من دواء تيسابري Tysabri أمرًا مهمًا، خاصة في الأشهر القليلة الأولى من العلاج. فمن الضروري الاستمرار في تناول الدواء طالما قررت أنت وطبيبك بأن هذا سوف يساعدك. فالمرضى الذين تلقوا جرعة واحدة أو جرعتين من تيسابري Tysabri &nbsp;ثم كانت هناك فجوة في العلاج لمدة ثلاثة أشهر أو أكثر، كانوا أكثر عرضةً لحدوث ردود الفعل التحسسيّة للدواء عند استئنافهم للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحقق من ردود الفعل التحسسيّة</strong></p><p dir="RTL">لقد ظهر رد فعل تحسسي لهذا الدواء لدى عدد قليل من المرضى. قد يتحقق طبيبك من ردود الفعل التحسسية أثناء الحقن ولمدة ساعة بعد ذلك. انظر أيضًا القسم 4، <em>الآثار الجانبية المحتملة</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول دواء تيسابري </strong><strong>Tysabri</strong></p><p dir="RTL">&nbsp;&nbsp;إذا نسيت أن تتناول جرعتك المعتادة من دواء تيسابري Tysabri فرتب مع طبيبك للحصول على هذه الجرعة في أسرع وقت ممكن. ويمكنك عندئذ الاستمرار في تناول جرعتك من دواء تيسابري Tysabri كل 4 أسابيع. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هل سوف يعمل دواء تيسابري </strong><strong>Tysabri</strong><strong> دائمًا</strong><strong>؟</strong></p><p dir="RTL">لدى عدد قليل من المرضى الذين يتلقون تيسابري Tysabri، قد تتسبب دفاعات الجسم الطبيعية في إيقاف الدواء عن العمل بشكل صحيح بمرور الوقت، حيث يعمل الجسم على إنشاء أجسام مضادة للدواء. يمكن لطبيبك أن يقرر ما إذا كان هذا الدواء لا يعمل بشكل صحيح بالنسبة لك من خلال فحوصات الدم وسيوقف العلاج، إذا لزم الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أسئلة أخرى متعلقة بالدواء تيسابري Tysabri اسأل طبيبك. استخدم هذا الدواء دائمًا تمامًا كما هو موصوف في هذه النشرة أو كما أخبرك طبيبك. استشر طبيبك إذا لم تكن متأكدًا.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كسائر الأدوية قد يتسبب هذا الدواء في أعراض جانبية على الرغم من أنه ليس بالضرورة أن كل شخص يختبر مثل هذه الأعراض</p><p dir="RTL">الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحدث إلى طبيبك أو الممرضة في الحال </strong>إذا لاحظت أي من الآثار التالية<strong>: </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>علامات التهاب المخ، تتضمن</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الشخصية والسلوك مثل الارتباك أو الهذيان أو فقدان الوعي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات (<em>نوبات صرع</em>)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان / القيء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب الرقبة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية المفرطة للضوء الساطع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي (<em>في أي مكان من الجسم</em>)</p><p dir="RTL">قد تكون هذه الأعراض ناجمة عن التهاب في المخ <em>(التهاب الدماغ أو </em><em>PML</em>) أو الطبقة التي تغطيها <em>(التهاب السحايا</em>).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علامات التهابات</strong><strong> خطيرة </strong><strong>أخرى</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى (ارتفاع درجة الحرارة) لا يوجد لها تفسير</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال شديد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة لفترة طويلة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكسل وفتور الهمة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف في النظر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع أو احمرار العين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong>&nbsp;<strong>علامات</strong><strong> </strong><strong>رد الفعل التحسسيّ</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح المصحوب بوخز (الطفح المصحوب ببثور)&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ الوجه أو الشفاه أو اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر أو عدم ارتياح في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة أو انخفاض في ضغط الدم (سوف يبُلغك طبيبك أو الممرضة بذلك في حالة قيامهم بمراقبة ضغط الدم لديك)&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">تظهر هذه العلامات على الأرجح أثناء أو بعد فترة وجيزة من الحقن.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علامات حول وجود مشكلة محتملة في الكبد:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار لون الجلد أو اصفرار المساحة البيضاء في بياض العينين&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لون داكن غير عادي للبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فحص وظائف الكبد غير الطبيعية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحدث إلى الطبيب أو الممرضة على الفور</strong> إذا أصبت بأي من الآثار الجانبية المذكورة أعلاه، أو إذا كنت تعتقد أنك مصاب بالتهاب. <strong>أظهر بطاقة تنبيه المريض</strong> ونشرة العبوة لأي طبيب أو ممرضة تتولى علاجك، وليس فقط لطبيب الأعصاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية أخرى</strong></p><p dir="RTL"><strong>شائعة جدًا</strong> قد تؤثر على أكثر من 1 من كل 10 أشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المسالك البولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتقان الحلق وسيلان الإفرازات من الأنف أو انسداد الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرغبة في التقيؤ (الغثيان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة، والشعور بالإعياء (<em>الغثيان</em>)، والحكة والقشعريرة أثناء أو بعد فترة وجيزة من الحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم (انخفاض في خلايا الدم الحمراء مما قد يجعل لون جلدك شاحب، ويمكن أن يجعلك تشعر بضيق التنفس أو نقص الطاقة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية (<em>فرط الحساسية</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح المصحوب بوخز )الطفح المصحوب ببثور)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرض (التقيؤ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس (<em>ضيق التنفس</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الوجه أو الجسم (<em>احمرار</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الهربس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الراحة حول مكان الحقن. قد تعاني من كدمات أو احمرار أو ألم أو حكة أو تورم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> قد تؤثر على ما يصل إلى 1 &nbsp;من كل 100 شخص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية الشديدة (<em>رد فعل تأقي</em> )</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الالتهاب المتقدم المتعدد البؤرات لمادة المخ البيضاء Progressive Multifocal leukoencephalopathy (PML)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطراب الالتهابي بعد التوقف عن تناول الدواء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في عدد خلايا الدم البيضاء (<em>فرط الحمضات</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفائح الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سهولة الإصابة بالكدمات (<em>فرفرية</em>)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;نادرة </strong>قد تؤثر على ما يصل إلى 1 &nbsp;من كل 1000 شخص :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الهربس في العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم الشديد (انخفاض في خلايا الدم الحمراء التي يمكن أن تجعل بشرتك شاحبة، ويمكن أن تجعلك تشعر بضيق في التنفس أو تفتقر إلى الطاقة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ شديد تحت الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات البيليروبين في الدم (فرط بيليروبين الدم) الذي قد يسبب أعراضًا مثل اصفرار العينين أو الجلد والحمى والتعب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة </strong>(لا يمكن تقدير وتيرة الحدوث من البيانات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب غير عادي (ما يسمى <em>&quot;الالتهابات الانتهازية&quot;</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تضرر الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحدث</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>في</strong><strong> </strong><strong>أسرع</strong><strong> </strong><strong>وقت</strong><strong> </strong><strong>ممكن</strong> إذا كنت تعتقد أنك مصاب بأي التهاب</p><p dir="RTL">سوف تجد أيضًا هذه المعلومات في بطاقة تنبيه المريض التي أعطاها لك طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا شعرت بأي أثار جانبية يرجى التحدث إلى طبيبك. يتضمن ذلك أيّ آثار جانبية محتملة لم يرد ذكرها في هذه النشرة. یمکنك أیضًا الإبلاغ عن الآثار الجانبية مباشرةً من خلال نظام الإبلاغ الوطني المدرج في القسم 6 من هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p>&nbsp;<p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong><strong>:</strong></p></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المملكة العربية السعودية:</strong></p><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز اتصالات الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; فاكس: +966-11-205-7662</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى و متناول الأطفال. لا تستعمل هذا الدواء من بعد تاريخ انتهاء الصلاحية المبين على العبوة الداخلية</p><p dir="RTL">والخارجية. يشير تاريخ انتهاء الصلاحية الى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القنينة الغير مفتوحة:</strong></p><p dir="RTL">تُخزن في ثلاجة (عند 2 درجة مئوية إلى 8 درجة مئوية).</p><p dir="RTL">لا يجب تجميد القنينة.</p><p dir="RTL">احتفظ بالقنينة في علبتها الخارجية بهدف حمايتها من تأثير الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحلول المخفف:</strong></p><p dir="RTL">بعد التخفيف، يوصى باستعمال الدواء فورًا. وفي حالة عدم استعماله فورًا يجب تخزين المحلول المخفف عند درجة حرارة من 2 إلى 8 درجة مئوية ثم حقنه بالتسريب الوريدي خلال 8 ساعات من تخفيفه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء إذا لاحظت تكوّن جسيمات في السائل و/أو إذا تغير لون السائل الموجود في القنينة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي ناتاليزوماب. كل قنينة سعة 15 ملليليتر من الخلاصة المركزة تحتوي على 300 مللغرام من ناتاليزوماب &nbsp;&nbsp;natalizumab 20) مللغرام /لكل &nbsp;ملليليتر). بعد التخفيف، فإن المحلول الصالح للحقن يحتوي تقريبا على 2.6 مللغرام / لكل ملليليتر من ناتاليزوماب .natalizumab</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">فوسفات الصوديوم، قاعدي أحادي، أحادي التميؤ</p><p dir="RTL">فوسفات الصوديوم، قاعدي ثنائي، سباعي التميؤ</p><p dir="RTL">كلوريد الصوديوم. (أنظر إلى الفقرة ٢ &rdquo;يحتوي Tysabri على صوديوم&ldquo;)</p><p dir="RTL">بولي صوربات 80 (E433)</p><p dir="RTL">ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تيسابري سائل رائق عديم اللون أو غائم قليلاً.</p><p dir="RTL">&nbsp;تحتوي كل علبة كرتونية على قنينة زجاجية واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مالك رخصة التسويق</strong><strong> </strong><strong>والمصنع المسؤول عن تحرير الصنف</strong></p><p dir="RTL">Biogen Netherlands B.V.</p><p dir="RTL">Prins Mauritslaan 13</p><p dir="RTL">1171 LP Badhoevedorp</p><p dir="RTL">The Netherlands</p><p dir="RTL">هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة للشكل </strong><strong>الصيدلاني</strong></p><p dir="RTL">Vetter Pharma-Fertigung GmbH &amp; Co. KG<br />Mooswiesen 2, 88214, Ravensburg.</p><p dir="RTL">Germany</p><p dir="RTL">ألمانيا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             05/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tysabri 300 mg concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL of concentrate contains 20 mg of natalizumab.

When diluted (see section 6.6), the solution for infusion contains approximately 2.6 mg per mL of natalizumab.

Natalizumab is a recombinant humanised anti α4 integrin antibody produced in a murine cell line by recombinant DNA technology.

Excipient with known effect

Each vial contains 2.3 mmol (or 52 mg) sodium  (see section 4.4 for further information).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.

Colourless, clear to slightly opalescent solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1)</p><p>or</p><p>&middot;&nbsp;&nbsp; Patients with rapidly evolving severe RRMS defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain Magnetic Resonance Imaging (MRI) or a significant increase in T2 lesion load as compared to a previous recent MRI.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy is to be initiated and continuously supervised by specialised physicians experienced in the diagnosis and treatment of neurological conditions, in centres with timely access to MRI.</p><p>&nbsp;</p><p>Patients treated with this medicinal product must be given the patient alert card and be informed about the risks of the medicinal product (see also package leaflet). After 2 years of treatment, patients should be re-informed about the risks, especially the increased risk of Progressive Multifocal Leukoencephalopathy (PML), and should be instructed together with their caregivers on early signs and symptoms of PML.</p><p>&nbsp;</p><p>Resources for the management of hypersensitivity reactions and access to MRI should be available.</p><p>&nbsp;</p><p>Some patients may have been exposed to immunosuppressive medicinal products (e.g. mitoxantrone, cyclophosphamide, azathioprine). These medicinal products have the potential to cause prolonged immunosuppression, even after dosing is discontinued. Therefore the physician must confirm that such patients are not immunocompromised before starting treatment &nbsp;(see section 4.4).</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>Tysabri 300&nbsp;mg is administered by intravenous infusion once every 4&nbsp;weeks.</p><p>&nbsp;</p><p>Continued therapy must be carefully reconsidered in patients who show no evidence of therapeutic benefit beyond 6&nbsp;months.</p><p>&nbsp;</p><p>Data on the safety and efficacy of natalizumab at 2&nbsp;years were generated from controlled, double&ndash;blind studies. After 2 years continued therapy should be considered only following a reassessment of the potential for benefit and risk. Patients should be re-informed about<strong> </strong>the risk factors for PML, like duration of treatment, immunosuppressant use prior to receiving the medicinal product and the presence of anti-John Cunningham virus (JCV) antibodies (see section 4.4).</p><p><u>&nbsp;</u></p><p><em><u>Readministration</u></em></p><p>&nbsp;</p><p>The efficacy of re-administration has not been established (for safety see section 4.4).</p><p>&nbsp;</p><p><u>Special populations </u></p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>&nbsp;</p><p>This medicinal product is not recommended for use in patients aged over 65 due to a lack of data in this population.</p><p>&nbsp;</p><p><em><u>Renal and hepatic impairment</u></em></p><p><u>&nbsp;</u></p><p>Studies have not been conducted to examine the effects of renal or hepatic impairment.</p><p>&nbsp;</p><p>The mechanism for elimination and results from population pharmacokinetics suggest that dose adjustment would not be necessary in patients with renal or hepatic impairment.</p><p><em>&nbsp;</em></p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p>The safety and efficacy of this medicinal product in children and adolescents up to 18 years have not been established. Currently available data are described in sections 4.8 and 5.1.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>This medicinal product is for intravenous use.</p><p>&nbsp;</p><p>For instructions on dilution of the medicinal product before administration (see section 6.6).</p><p>&nbsp;</p><p>After dilution (see section 6.6), the infusion is to be administered over approximately 1&nbsp;hour and patients are to be observed during the infusion and for 1&nbsp;hour after the completion of the infusion for signs and symptoms of hypersensitivity reactions.</p><p>&nbsp;</p><p>After the first 12 intravenous Tysabri doses, patients should continue to be observed during infusion. If the patients have not experienced any infusion reactions, the post dose observation time may be reduced or removed according to clinical judgement.</p><p>&nbsp;</p><p>Patients restarting natalizumab treatment after a treatment gap &ge;&nbsp;6 months are to be observed during the infusion and for 1&nbsp;hour after the completion of the infusion for signs and symptoms of hypersensitivity reactions for the first 12 intravenous infusions after restarting therapy.</p><p>&nbsp;</p><p>Tysabri 300&nbsp;mg concentrate for solution for infusion must not be administered as a bolus injection.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Progressive multifocal leukoencephalopathy (PML).

Patients with increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies (see sections 4.4 and 4.8).

Combination with other DMTs.

Known active malignancies, except for patients with cutaneous basal cell carcinoma.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and batch number of the administered product should be clearly recorded.</p><p><u>&nbsp;</u></p><p><u>Progressive Multifocal Leukoencephalopathy (PML)</u></p><p>&nbsp;</p><p>Use of this medicinal product has been associated with an increased risk of PML,<strong> </strong>an opportunistic infection caused by JC virus, which may be fatal or result in severe disability. Due to this increased risk of developing PML, the benefits and risks of treatment should be individually reconsidered by the specialist physician and the patient; patients must be monitored at regular intervals throughout and should be instructed together with their caregivers on early signs and symptoms of PML. JC virus also causes JCV granule cell neuronopathy (GCN) which has been reported in patients treated with this medicinal product. Symptoms of JCV GCN are similar to symptoms of PML (i.e. cerebellar syndrome).</p><p>&nbsp;</p><p>The following risk factors are associated with an increased risk of PML:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; The presence of anti-JCV antibodies.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Treatment duration, especially beyond 2 years. After 2 years all patients should be re-informed about the risk of PML with the medicinal product.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Immunosuppressant use prior to receiving the medicinal product.</p><p>&nbsp;</p><p>Patients who are anti-JCV antibody positive are at an increased risk of developing PML compared to patients who are anti-JCV antibody negative. Patients who have all three risk factors for PML (i.e., are anti-JCV antibody positive <strong>and </strong>have received more than 2 years of therapy with this medicinal product <strong>and </strong>have received prior immunosuppressant therapy) have a significantly higher risk of PML.</p><p>&nbsp;</p><p>In anti-JCV antibody positive natalizumab treated patients who have not used prior immunosuppressants the level of anti-JCV antibody response (index) is associated with the level of risk for PML.</p><p>&nbsp;</p><p>In anti-JCV antibody positive patients, extended interval dosing of Tysabri (average dosing interval of approximately 6 weeks) is suggested to be associated with a lower PML risk compared to approved dosing. If utilising extended interval dosing, caution is required because the efficacy of extended interval dosing has not been established and the associated benefit/risk balance is currently unknown (see section 5.1, <em>Intravenous administration Q6W</em>). For further information, refer to the Physician Information and Management Guidelines.</p><p>&nbsp;</p><p>Patients considered at high risk treatment with this treatment should only be continued if the benefits outweigh the risks. For the estimation of PML risk in the different patient subgroups, please refer to the Physician Information and Management Guidelines.</p><p>&nbsp;</p><p><u>Anti-JCV antibody testing</u></p><p>&nbsp;</p><p>Anti-JCV antibody testing provides supportive information for risk stratification of treatment with this medicinal product. Testing for serum anti-JCV antibody prior to initiating therapy or in patients receiving the medicinal product with an unknown antibody status is recommended. Anti-JCV antibody negative patients may still be at risk of PML for reasons such as a new JCV infection, fluctuating antibody status or a false negative test result. Re-testing of anti-JCV antibody negative patients every 6 months is recommended. Retesting low index patients who have no history of prior immunosuppressant use every 6 months once they reach the 2 year treatment point is recommended.</p><p>&nbsp;</p><p>The anti-JCV antibody assay (ELISA) should not be used to diagnose PML. Use of plasmapheresis/plasma exchange (PLEX) or intravenous immunoglobulin (IVIg) can affect meaningful interpretation of serum anti-JCV antibody testing. Patients should not be tested for anti-JCV antibodies within 2 weeks of PLEX due to removal of antibodies from the serum, or within 6 months of IVIg (i.e. 6 months = 5x half-life for immunoglobulins).&nbsp;&nbsp;</p><p>&nbsp;</p><p>For further information on anti-JCV antibody testing please see Physician Information and Management Guidelines.</p><p>&nbsp;</p><p><u>MRI screening for PML</u></p><p>&nbsp;</p><p>Before initiation of treatment with this medicinal product, a recent (usually within 3 months) MRI should be available as a reference, and be repeated at least on a yearly basis. More frequent MRIs (e.g. on a 3 to 6 monthly basis) using an abbreviated protocol should be considered for patients at higher risk of PML. This includes:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Patients who have all three risk factors for PML (i.e., are<s> </s>anti-JCV antibody positive <strong>and </strong>have received more than 2 years of &nbsp;therapy with this medicinal product <strong>and </strong>have received prior immunosuppressant therapy),</p><p>or</p><p>&middot;&nbsp;&nbsp; Patients with a high anti-JCV antibody index who have received more than 2 years of therapy with this medicinal product and without prior history of immunosuppressant therapy.</p><p>&nbsp;</p><p>Current evidence suggests that the risk of PML is low at an index equal to or below 0.9 and increases substantially above 1.5 for patients who have been on treatment with this medicinal product for longer than 2 years (see the Physician Information and Management Guidelines for further information).</p><p>&nbsp;</p><p>No studies have been performed to evaluate the efficacy and safety of natalizumab when switching patients from DMTs with an immunosuppressant effect. It is unknown if patients switching from these therapies to this treatment have an increased risk of PML, therefore these patients should be monitored more frequently (i.e. similarly to patients switching from immunosuppressants to natalizumab).</p><p>&nbsp;</p><p>PML should be considered as a differential diagnosis in any MS patient taking Tysabri presenting with neurological symptoms and/or new brain lesions in MRI. Cases of asymptomatic PML based on MRI and positive JCV DNA in the cerebrospinal fluid have been reported.</p><p>&nbsp;</p><p>Physicians should refer to the Physician Information and Management Guidelines for further information on managing the risk of PML in natalizumab-treated patients.&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>If PML or JCV GCN is suspected, further dosing must be suspended until PML has been excluded. </strong></p><p>&nbsp;</p><p>The clinician should evaluate the patient to determine if the symptoms are indicative of neurological dysfunction and, if so, whether these symptoms are typical of MS or possibly suggestive of PML or JCV GCN. If any doubt exists, further evaluation, including MRI scan preferably with contrast (compared with pre-treatment baseline MRI), CSF testing for JC Viral DNA and repeat neurological assessments, should be considered as described in the Physician Information and Management Guidelines (see Educational guidance). Once the clinician has excluded PML and/or JCV GCN (if necessary, by repeating clinical, imaging and/or laboratory investigations if clinical suspicion remains), dosing may resume.</p><p>&nbsp;</p><p>The physician should be particularly alert to symptoms suggestive of PML or JCV GCN that the patient may not notice (e.g. cognitive, psychiatric symptoms or cerebellar syndrome). Patients should also be advised to inform their partner or caregivers about their treatment, since they may notice symptoms that the patient is not aware of.</p><p>&nbsp;</p><p>PML has been reported following discontinuation of this medicinal product in patients who did not have findings suggestive of PML at the time of discontinuation. Patients and physicians should continue to follow the same monitoring protocol and be alert for any new signs or symptoms that may be suggestive of PML for approximately 6 months following discontinuation of TYSABRI.</p><p>&nbsp;</p><p>If a patient develops PML the dosing of natalizumab must be permanently discontinued.</p><p>&nbsp;</p><p>Following reconstitution of the immune system in immunocompromised patients with PML improved outcome has been seen.</p><p>&nbsp;</p><p>Based on a retrospective analysis of natalizumab-treated patients since its approval, no difference was observed on 2-year survival after PML diagnosis between patients who received PLEX and those who did not. For other considerations on the management of PML, see the Physician Information and Management Guidelines.</p><p>&nbsp;</p><p><u>PML and IRIS (Immune Reconstitution Inflammatory Syndrome)</u></p><p><u>&nbsp;</u></p><p>IRIS occurs in almost all PML patients treated with this medicinal product after withdrawal or removal of the medicinal product. IRIS is thought to result from the restoration of immune function in patients with PML, which can lead to serious neurological complications and may be fatal. Monitoring for development of IRIS and appropriate treatment of the associated inflammation during recovery from PML should be undertaken (see the Physician Information and Management Guidelines for further information).</p><p><u>&nbsp;</u></p><p><u>Infections including other opportunistic infections</u></p><p><u>&nbsp;</u></p><p>Other opportunistic infections have been reported with use of this medicinal product, primarily in patients with Crohn&rsquo;s disease who were immunocompromised or where significant co‑morbidity existed, however increased risk of other opportunistic infections with use of the medicinal product in patients without these co-morbidities cannot currently be excluded. Opportunistic infections were also detected in MS patients treated with this medicinal product as a monotherapy (see section 4.8).</p><p>&nbsp;</p><p>This treatment increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella zoster viruses. Serious, life-threatening, and sometimes fatal cases have been reported in the postmarketing setting in multiple sclerosis patients receiving the treatment (see section 4.8). If herpes encephalitis or meningitis occurs, the medicinal product should be discontinued, and appropriate treatment for herpes encephalitis or meningitis should be administered.</p><p>&nbsp;</p><p>Acute retinal necrosis (ARN) is a rare fulminant viral infection of the retina caused by the family of herpes viruses (e.g. varicella zoster). ARN has been observed in patients being administered this medicinal product and can be potentially blinding. Patients presenting with eye symptoms such as decreased visual acuity, redness and painful eye should be referred for retinal screening for ARN. Following clinical diagnosis of ARN, discontinuation of this medicinal product should be considered in these patients.</p><p>&nbsp;</p><p>Prescribers should be aware of the possibility that other opportunistic infections may occur during therapy and should include them in the differential diagnosis of infections that occur in natalizumab‑treated patients. If an opportunistic infection is suspected, dosing is to be suspended until such infections can be excluded through further evaluations.</p><p>&nbsp;</p><p>If a patient receiving this medicinal product develops an opportunistic infection, dosing of the medicinal product must be permanently discontinued.</p><p><u>&nbsp;</u></p><p><u>Educational guidance</u></p><p><u>&nbsp;</u></p><p>All physicians who intend to prescribe the medicinal product must ensure they are familiar with the Physician Information and Management Guidelines.</p><p>&nbsp;</p><p>Physicians must discuss the benefits and risks of natalizumab therapy with the patient and provide them with a patient alert card. Patients should be instructed that if they develop any infection then they should inform their physician that they are being treated with this medicinal product.</p><p>&nbsp;</p><p>Physicians should counsel patients on the importance of uninterrupted dosing, particularly in the early months of treatment (see hypersensitivity).</p><p><u>&nbsp;</u></p><p><u>Hypersensitivity</u></p><p>&nbsp;</p><p>Hypersensitivity reactions have been associated with this medicinal product, including serious systemic reactions (see section 4.8). These reactions usually occurred during the infusion or up to 1&nbsp;hour after completion of the infusion. The risk for hypersensitivity was greatest with early infusions and in patients re-exposed to treatment following an initial short exposure (one or two infusions) and extended period (three months or more) without treatment. However, the risk of hypersensitivity reactions should be considered for every infusion administered.</p><p>&nbsp;</p><p>Patients are to be observed during the infusion and for 1&nbsp;hour after the completion of the infusion (see section 4.8). Resources for the management of hypersensitivity reactions should be available.</p><p>&nbsp;</p><p>This product should be discontinued and appropriate therapy initiated at the first symptoms or signs of hypersensitivity.</p><p>&nbsp;</p><p>Patients who have experienced a hypersensitivity reaction must be permanently discontinued from treatment with natalizumab.</p><p>&nbsp;</p><p><u>Concurrent treatment with immunosuppressants</u></p><p><u>&nbsp;</u></p><p>The safety and efficacy of this medicinal product in combination with other immunosuppressive and antineoplastic therapies have not been fully established. Concurrent use of these agents with this medicinal product may increase the risk of infections, including opportunistic infections, and is contraindicated (see section 4.3).</p><p>&nbsp;</p><p>In phase 3 MS clinical trials with natalizumab intravenous infusion, concomitant treatment of relapses with a short course of corticosteroids was not associated with an increased rate of infection. Short courses of corticosteroids can be used in combination with this medicinal product.</p><p>&nbsp;</p><p><u>Prior treatment with immunosuppressive or immunomodulatory therapies </u></p><p>&nbsp;</p><p>Patients with a treatment history of immunosuppressant medications are at increased risk for PML.</p><p>No studies have been performed to evaluate the efficacy and safety of the medicinal product when switching patients from DMTs with an immunosuppressant effect. It is unknown if patients switching from these therapies to this medicinal product have an increased risk of PML, therefore these patients should be monitored more frequently (i.e. similarly to patients switching from immunosuppressants to this medicinal product, see MRI screening for PML).</p><p>&nbsp;</p><p>Care should be taken with patients who have previously received immunosuppressants to allow sufficient time for immune function recovery to occur. Physicians must evaluate each individual case to determine whether there is evidence of an immunocompromised state prior to commencing treatment (see section 4.3).</p><p>&nbsp;</p><p>When switching patients from another DMT to this medicinal product, the half-life and mode of action of the other therapy must be considered in order to avoid an additive immune effect whilst at the same time minimising the risk of disease reactivation. A Complete Blood Count (CBC, including lymphocytes) is recommended prior to initiating treatment to ensure that immune effects of the previous therapy (i.e. cytopenia) have resolved.</p><p>&nbsp;</p><p>Patients can switch directly from beta interferon or glatiramer acetate to natalizumab providing there are no signs of relevant treatment-related abnormalities e.g. neutropenia and, lymphopenia.</p><p>&nbsp;</p><p>When switching from dimethyl fumarate, the washout period should be sufficient for lymphocyte count to recover before treatment is started.</p><p>&nbsp;</p><p>Following discontinuation of fingolimod, lymphocyte count progressively returns to normal range within 1 to 2 months after stopping therapy. The washout period should be sufficient for lymphocyte count to recover before treatment is started.</p><p>&nbsp;</p><p>Teriflunomide is eliminated slowly from the plasma. Without an accelerated elimination procedure, clearance of teriflunomide from plasma can take from several months up to 2 years. An accelerated elimination procedure as defined in the teriflunomide Summary of Product Characteristics is recommended or alternatively washout period should not be shorter than 3.5 months. Caution regarding potential concomitant immune effects is required when switching patients from teriflunomide to this medicinal product.</p><p>&nbsp;</p><p>Alemtuzumab has profound prolonged immunosuppressive effects. As the actual duration of these effects is unknown, initiating treatment with this medicinal product after alemtuzumab is not recommended unless the benefits clearly outweigh the risks for the individual patient.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p><u>&nbsp;</u></p><p>Disease exacerbations or infusion related events may indicate the development of antibodies against natalizumab. In these cases the presence of antibodies should be evaluated and if these remain positive in a confirmatory test after at least 6&nbsp;weeks, treatment should be discontinued, as persistent antibodies are associated with a substantial decrease in efficacy of this medicinal product and an increased incidence of hypersensitivity reactions (see section 4.8).</p><p>&nbsp;</p><p>Since patients who have received an initial short exposure to this medicinal product and then had an extended period without treatment are at a higher risk of developing anti-natalizumab antibodies and/or hypersensitivity upon redosing, the presence of antibodies should be evaluated and if these remain positive in a confirmatory test after at least 6 weeks, the patient should not receive further treatment with natalizumab (see section 5.1).</p><p>&nbsp;</p><p><u>Hepatic events</u></p><p>&nbsp;</p><p>Spontaneous serious adverse reactions of liver injury have been reported during the post-marketing phase (see section 4.8). These liver injuries may occur at any time during treatment, even after the first dose. In some instances, the reaction reoccurred when treatment was reintroduced. Some patients with a past medical history of an abnormal liver test have experienced an exacerbation of abnormal liver test while on treatment. Patients should be monitored as appropriate for impaired liver function, and be instructed to contact their physician in case signs and symptoms suggestive of liver injury occur, such as jaundice and vomiting. In cases of significant liver injury this medicinal product should be discontinued.</p><p>&nbsp;</p><p><u>Thrombocytopenia</u></p><p><u>&nbsp;</u></p><p>Thrombocytopenia, including immune thrombocytopenic purpura (ITP), has been reported with the use of natalizumab. Delay in the diagnosis and treatment of thrombocytopenia may lead to serious and life-threatening sequelae. Patients should be instructed to report to their physician immediately if they experience any signs of unusual or prolonged bleeding, petechiae, or spontaneous bruising. If thrombocytopenia is identified, discontinuation of natalizumab should be considered.</p><p><u>&nbsp;</u></p><p><u>Stopping therapy</u></p><p>&nbsp;</p><p>If a decision is made to stop treatment with natalizumab, the physician needs to be aware that natalizumab remains in the blood, and has pharmacodynamic effects (e.g increased lymphocyte counts) for approximately 12&nbsp;weeks following the last dose. Starting other therapies during this interval will result in a concomitant exposure to natalizumab. For medicinal products such as interferon and glatiramer acetate, concomitant exposure of this duration was not associated with safety risks in clinical trials. No data are available in MS patients regarding concomitant exposure with immunosuppressant medication. Use of these medicinal products soon after the discontinuation of natalizumab may lead to an additive immunosuppressive effect. This should be carefully considered on a case‑by‑case basis, and a wash-out period of natalizumab might be appropriate. Short courses of steroids used to treat relapses were not associated with increased infections in clinical trials.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p><u>&nbsp;</u></p><p>Before dilution, this medicinal product contains 52&nbsp;mg sodium per vial of medicinal product, equivalent to 2.6% of the WHO recommended maximum daily intake of 2&nbsp;g sodium for an adult.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Natalizumab is contraindicated in combination with other DMTs (see section 4.3).</p><p>&nbsp;</p><p><u>Immunisations</u></p><p><u>&nbsp;</u></p><p>In a randomised, open label study of 60 patients with relapsing MS there was no significant difference in the humoral immune response to a recall antigen (tetanus toxoid) and only slightly slower and reduced humoral immune response to a neoantigen (keyhole limpet haemocyanin) was observed in patients who were treated with this medicinal product for 6 months compared to an untreated control group. Live vaccines have not been studied.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential </u></p><p><u>&nbsp;</u></p><p>If a woman becomes pregnant while taking this medicinal product, discontinuation should be considered. A benefit/risk evaluation of the use of this medicinal product during pregnancy should take into account the patient&rsquo;s clinical condition and the possible return of disease activity after stopping the medicinal product.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>Data from clinical trials, a prospective pregnancy registry, post-marketing cases and available literature do not suggest an effect of natalizumab exposure on pregnancy outcomes.</p><p><u>&nbsp;</u></p><p>The completed prospective Tysabri pregnancy registry contained 355 pregnancies with available outcomes. There were 316 live births, 29 of which were reported to have birth defects. Sixteen of the 29 were classified as major defects. The rate of defects corresponds to the defect rates reported in other pregnancy registries involving MS patients. There is no evidence of a specific pattern of birth defects with this medicinal product.</p><p>&nbsp;</p><p>There are no adequate and well-controlled studies of natalizumab therapy in pregnant women.</p><p>&nbsp;</p><p>Thrombocytopenia and anaemia in infants born to women exposed to natalizumab during pregnancy were reported in the postmarketing setting. Monitoring of platelet counts and haemoglobin is recommended in neonates born to women exposed to natalizumab during pregnancy.</p><p>&nbsp;</p><p>This drug should be used during pregnancy only if clearly needed. If a woman becomes pregnant while taking natalizumab, discontinuation of natalizumab should be considered.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Natalizumab is excreted in human milk. The effect of natalizumab on newborn/infants is unknown. Breast-feeding should be discontinued during treatment with &nbsp;natalizumab.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>&nbsp;</p><p>Reductions in female guinea pig fertility were observed in one study at doses in excess of the human dose; natalizumab did not affect male fertility. It is considered unlikely that natalizumab will affect fertility performance in humans following the maximum recommended dose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tysabri has a minor influence on the ability to drive and use machines. Dizziness may occur following administration of this medicinal product (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>In placebo-controlled trials in 1,617 MS patients treated with natalizumab for up to 2&nbsp;years (placebo: 1,135), adverse events leading to discontinuation of therapy occurred in 5.8% of patients treated with natalizumab (placebo: 4.8%). Over the 2‑year duration of the studies, 43.5% of patients treated with natalizumab reported adverse reactions (placebo: 39.6%).</p><p>&nbsp;</p><p>In clinical trials in 6786 patients treated with natalizumab (intravenous infusion and subcutaneous injection), the most frequently occurring adverse reactions were headache (32%), nasopharyngitis (27%), fatigue (23%), urinary tract infection (16%), nausea (15%), arthralgia (14%), and dizziness (11%) associated with natalizumab administration.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions arising from clinical studies, post-authorisation safety studies and spontaneous reports are presented in Table 1, below. Within the system organ classes they are listed under the following headings: Very common (&ge;1/10); Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1,000); Very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1: Adverse reactions </strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>MedDRA System Organ Class</p></td><td colspan="6" style="vertical-align:top"><p>Frequency of adverse reactions</p></td></tr><tr><td style="vertical-align:top"><p><em>Very Common</em></p></td><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p><em>Not known</em></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Infections and infestations</em></p></td><td style="vertical-align:top"><p>Nasopharyngitis</p><p>Urinary tract infection</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Herpes infection</p></td><td style="vertical-align:top"><p>Progressive multifocal leukoencephalopathy</p></td><td style="vertical-align:top"><p>Herpes ophthalmic</p></td><td style="vertical-align:top"><p>Meningoencephalitis herpetic</p><p>JC virus granule cell neuropathy</p><p>Necrotising herpetic retinopathy</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p><p>Immune reconstitution inflammatory syndrome</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Thrombocytopenia,</p><p>Immune thrombocytopenic purpura (ITP)</p><p>Eosinophilia</p></td><td style="vertical-align:top"><p>Haemolytic anaemia</p><p>Nucleated red cells</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperbilirubinaemia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver injury</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Investigations </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased</p><p>Drug specific antibody present</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Injury, poisoning and procedural complications </em></p></td><td style="vertical-align:top"><p>Infusion related reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Pyrexia</p><p>Chills</p><p>Infusion site reaction</p><p>Injection site reaction</p></td><td style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Rash</p><p>Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p>Dizziness</p><p>Headache</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td><td style="vertical-align:top"><p>Arthralgia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em><u>Infusion-related reactions (IRR)</u></em></p><p>&nbsp;</p><p>In 2-year controlled clinical trials in MS patients, an infusion‑related event was defined as an adverse event occurring during the infusion or within 1&nbsp;hour of the completion of the infusion. These occurred in 23.1% of MS patients treated with natalizumab (placebo: 18.7%). Events reported more commonly with natalizumab than with placebo included dizziness, nausea, urticaria and rigors.</p><p>&nbsp;</p><p><em><u>Hypersensitivity reactions</u></em></p><p>&nbsp;</p><p>In 2-year controlled clinical trials in MS patients, hypersensitivity reactions occurred in up to 4% of patients. Anaphylactic/anaphylactoid reactions occurred in less than 1% of patients receiving &nbsp;this medicinal product. Hypersensitivity reactions usually occurred during the infusion or within the 1‑hour period after the completion of the infusion (see section 4.4). In post-marketing experience, there have been reports of hypersensitivity reactions which have occurred with one or more of the following associated symptoms: hypotension, hypertension, chest pain, chest discomfort, dyspnoea, angioedema, in addition to more usual symptoms such as rash and urticaria.</p><p>&nbsp;</p><p><em><u>Immunogenicity</u></em></p><p>&nbsp;</p><p>In 10% of patients antibodies against natalizumab were detected in 2-year controlled clinical trials in MS patients. Persistent anti-natalizumab antibodies (one positive test reproducible on retesting at least 6&nbsp;weeks later) developed in approximately 6% of patients. Antibodies were detected on only one occasion in an additional 4% of patients. Persistent antibodies were associated with a substantial decrease in the effectiveness of natalizumab and an increased incidence of hypersensitivity reactions. Additional infusion-related reactions associated with persistent antibodies included rigors, nausea, vomiting and flushing (see section 4.4).</p><p>&nbsp;</p><p>If, after approximately 6&nbsp;months of therapy, persistent antibodies are suspected, either due to reduced efficacy or due to occurrence of infusion-related events, they may be detected and confirmed with a subsequent test 6&nbsp;weeks after the first positive test. Given that efficacy may be reduced or the incidence of hypersensitivity or infusion-related reactions may be increased in a patient with persistent antibodies, treatment should be discontinued in patients who develop persistent antibodies.</p><p><strong>&nbsp;</strong></p><p><em><u>Infections, including PML and opportunistic infections</u></em></p><p><strong>&nbsp;</strong></p><p>In 2-year controlled clinical trials in MS patients, the rate of infection was approximately 1.5 per patient‑year in both natalizumab- and placebo‑treated patients. The nature of the infections was generally similar in natalizumab- and placebo‑treated patients. A case of <em>cryptosporidium</em> diarrhoea was reported in MS clinical trials. In other clinical trials, cases of additional opportunistic infections have been reported, some of which were fatal. The majority of patients did not interrupt natalizumab therapy during infections and recovery occurred with appropriate treatment.</p><p>&nbsp;</p><p>In clinical trials, herpes infections (Varicella-Zoster virus, Herpes-simplex virus) occurred slightly more frequently in natalizumab-treated patients than in placebo-treated patients. In post-marketing experience, serious, life-threatening, and sometimes fatal cases of encephalitis and meningitis caused by herpes simplex or varicella zoster have been reported in multiple sclerosis patients receiving natalizumab. The duration of treatment with natalizumab prior to onset ranged from a few months to several years (see section 4.4).</p><p>&nbsp;</p><p>In postmarketing experience, rare cases of ARN have been observed in patients receiving this medicinal product. Some cases have occurred in patients with central nervous system (CNS) herpes infections (e.g. herpes meningitis and encephalitis). Serious cases of ARN, either affecting one or both eyes, led to blindness in some patients. The treatment reported in these cases included anti-viral therapy and in some cases, surgery (see section 4.4).</p><p>&nbsp;</p><p>Cases of PML have been reported from clinical trials, post-marketing observational studies and post-marketing passive surveillance. PML usually leads to severe disability or<em> </em>death (see section 4.4). Cases of JCV GCN have also been reported during postmarketing use of Tysabri. Symptoms of JCV GCN are similar to PML.</p><p>&nbsp;</p><p><em><u>Hepatic events</u></em></p><p>&nbsp;</p><p>Spontaneous cases of serious liver injuries, increased liver enzymes, hyperbilirubinaemia have been reported during the post-marketing phase (see section 4.4).</p><p>&nbsp;</p><p><em><u>Anaemia and haemolytic anaemia</u></em></p><p>&nbsp;</p><p>Rare, serious cases of anaemia and haemolytic anaemia have been reported in patients treated with this medicinal product in post-marketing observational studies.</p><p>&nbsp;</p><p><em><u>Malignancies</u></em></p><p>&nbsp;</p><p>No differences in incidence rates or the nature of malignancies between natalizumab- and placebo‑treated patients were observed over 2&nbsp;years of treatment. However, observation over longer treatment periods is required before any effect of natalizumab on malignancies can be excluded (see section 4.3).</p><p><em>&nbsp;</em></p><p><em><u>Effects on laboratory tests</u></em></p><p><em><u>&nbsp;</u></em></p><p>In 2-year controlled clinical trials in MS patients treatment with natalizumab was associated with increases in circulating lymphocytes, monocytes, eosinophils, basophils and nucleated red blood cells. Elevations in neutrophils were not seen. Increases from baseline for lymphocytes, monocytes, eosinophils and basophils ranged from 35% to 140% for individual cell types but mean cell counts remained within normal ranges with IV administration. During treatment with IV form of this medicinal product, small reductions in haemoglobin (mean decrease 0.6&nbsp;g/dL), haematocrit (mean decrease 2%) and red blood cell counts (mean decrease 0.1&nbsp;x&nbsp;10<sup>6</sup>/L) were seen. All changes in haematological variables returned to pre‑treatment values, usually within 16&nbsp;weeks of last dose of the medicinal product and the changes were not associated with clinical symptoms. In post-marketing experience, there have also been reports of eosinophilia (eosinophil count &gt;1,500/mm<sup>3</sup>) without clinical symptoms. In such cases where therapy was discontinued the elevated eosinophil levels resolved.</p><p>&nbsp;</p><p><em><u>Thrombocytopenia</u></em></p><p><em><u>&nbsp;</u></em></p><p>In post-marketing experience, thrombocytopenia and immune thrombocytopenic purpura (ITP) have been reported with uncommon frequency.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><strong>&nbsp;</strong></p><p>Serious adverse events were evaluated in 621 MS paediatric patients included in a meta-analysis (see also section 5.1). Within the limitations of these data, there were no new safety signals identified in this patient population.<u> </u>1 case of&nbsp;herpes meningitis was reported in the meta-analysis. No cases of PML were identified in the meta-analysis, however, PML has been reported in natalizumab-treated paediatric patients in the post-marketing setting.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect (s):</strong></p><p><strong>&nbsp;</strong></p><ul><li><strong>Saudi Arabia:</strong></li></ul><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Safety of doses higher than 300 mg has not been adequately evaluated. The maximum amount of natalizumab that can be safely administered has not been determined.</p><p>There is no known antidote for natalizumab overdose. Treatment consists of discontinuation of the medicinal product and supportive therapy as needed.<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, selective immunosuppressants, ATC code: L04AA23</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>Natalizumab is a selective adhesion-molecule inhibitor and binds to the &alpha;4‑subunit of human integrins, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils. Specifically, natalizumab binds to the &alpha;4&beta;1 integrin, blocking the interaction with its cognate receptor, vascular cell adhesion molecule‑1 (VCAM‑1), and ligands osteopontin, and an alternatively spliced domain of fibronectin, connecting segment‑1 (CS‑1). Natalizumab blocks the interaction of &alpha;4&beta;7 integrin with the mucosal addressin cell adhesion molecule‑1 (MadCAM‑1). Disruption of these molecular interactions prevents transmigration of mononuclear leukocytes across the endothelium into inflamed parenchymal tissue. A further mechanism of action of natalizumab may be to suppress ongoing inflammatory reactions in diseased tissues by inhibiting the interaction of &alpha;4‑expressing leukocytes with their ligands in the extracellular matrix and on parenchymal cells. As such, natalizumab may act to suppress inflammatory activity present at the disease site, and inhibit further recruitment of immune cells into inflamed tissues.</p><p>&nbsp;</p><p>In MS, lesions are believed to occur when activated T‑lymphocytes cross the blood‑brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells and endothelial cells of the vessel wall. The interaction between &alpha;4&beta;1 and its targets is an important component of pathological inflammation in the brain and disruption of these interactions leads to reduced inflammation. Under normal conditions, VCAM‑1 is not expressed in the brain parenchyma. However, in the presence of pro‑inflammatory cytokines, VCAM‑1 is upregulated on endothelial cells and possibly on glial cells near the sites of inflammation. In the setting of central nervous system (CNS) inflammation in MS, it is the interaction of &alpha;4&beta;1 with VCAM‑1, CS‑1 and osteopontin that mediates the firm adhesion and transmigration of leukocytes into the brain parenchyma and may perpetuate the inflammatory cascade in CNS tissue. Blockade of the molecular interactions of &alpha;4&beta;1 with its targets reduces inflammatory activity present in the brain in MS and inhibits further recruitment of immune cells into inflamed tissue, thus reducing the formation or enlargement of MS lesions.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p>&nbsp;</p><p><em><u>AFFIRM clinical study</u></em></p><p><u>&nbsp;</u></p><p>Efficacy as monotherapy has been evaluated in one randomised, double‑blind, placebo‑controlled study lasting 2&nbsp;years (AFFIRM study)<strong> </strong>in RRMS patients who had experienced at least 1&nbsp;clinical relapse during the year prior to entry and had a Kurtzke Expanded Disability Status Scale (EDSS) score between 0 and 5. Median age was 37&nbsp;years, with a median disease duration of 5&nbsp;years. The patients were randomised with a 2:1 ratio to receive Tysabri 300&nbsp;mg (n&nbsp;=&nbsp;627) or placebo (n&nbsp;=&nbsp;315) every 4&nbsp;weeks for up to 30&nbsp;infusions. Neurological evaluations were performed every 12&nbsp;weeks and at times of suspected relapse. MRI evaluations for T1‑weighted gadolinium (Gd)‑enhancing lesions and T2‑hyperintense lesions were performed annually.</p><p>&nbsp;</p><p>Study features and results are presented in the Table 2.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3"><p><strong>Table 2. &nbsp;</strong><strong>AFFIRM study: Main features and results</strong></p></td><td><p>&nbsp;</p></td></tr></thead><tbody><tr><td><p>Design</p></td><td colspan="3"><p>Monotherapy; randomised double-blind placebo-controlled parallel-group trial for 120 weeks</p></td></tr><tr><td><p>Subjects</p></td><td colspan="3"><p>RRMS (McDonald criteria)</p></td></tr><tr><td><p>Treatment</p></td><td colspan="3"><p>Placebo / Natalizumab 300&nbsp;mg i.v. every 4 weeks</p></td></tr><tr><td><p>One year endpoint</p></td><td colspan="3"><p>Relapse rate</p></td></tr><tr><td><p>Two year endpoint</p></td><td colspan="3"><p>Progression on EDSS</p></td></tr><tr><td><p>Secondary endpoints</p></td><td colspan="3"><p>Relapse rate derived variables / MRI-derived variables</p></td></tr><tr><td><p>Subjects</p></td><td><p>Placebo</p></td><td colspan="2"><p>Natalizumab</p></td></tr><tr><td><p>Randomised</p></td><td><p>315</p></td><td colspan="2"><p>627</p></td></tr><tr><td><p>Completing 1 years&nbsp;</p></td><td><p>296</p></td><td colspan="2"><p>609</p></td></tr><tr><td><p>Completing 2 years&nbsp;</p></td><td><p>285</p></td><td colspan="2"><p>589</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Age yrs, median (range)</p></td><td><p>37 (19-50)</p></td><td colspan="2"><p>36 (18-50)</p></td></tr><tr><td><p>MS-history yrs, median (range)</p></td><td><p>6.0 (0-33)</p></td><td colspan="2"><p>5.0 (0-34)</p></td></tr><tr><td><p>Time since diagnosis, yrs median (range)</p></td><td><p>2.0 (0-23)</p></td><td colspan="2"><p>2.0 (0-24)</p></td></tr><tr><td><p>Relapses in previous 12 months,</p><p>median (range)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.0 (0-5)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>1.0 (0-12)</p></td></tr><tr><td><p>EDSS-baseline, median (range)</p></td><td><p>2 (0-6.0)</p></td><td colspan="2"><p>2 (0-6.0)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>RESULTS</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Annual relapse rate</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>After one year (primary endpoint)&nbsp;</p></td><td><p>0.805</p></td><td colspan="2"><p>0.261</p></td></tr><tr><td><p>After two years</p></td><td><p>0.733</p></td><td colspan="2"><p>0.235</p></td></tr><tr><td><p>One year&nbsp;</p></td><td colspan="3"><p>Rate ratio 0.33 CI<sub>95%</sub> 0.26 ; 0.41</p></td></tr><tr><td><p>Two years</p></td><td colspan="3"><p>Rate ratio 0.32 CI<sub>95%</sub> 0.26 ; 0.40</p></td></tr><tr><td><p>Relapse free</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>After one year&nbsp;</p></td><td><p>53%</p></td><td colspan="2"><p>76%</p></td></tr><tr><td><p>After two years</p></td><td><p>41%</p></td><td colspan="2"><p>67%</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Disability</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Proportion progressed<sup>1</sup>(12-week confirmation; primary outcome)</p></td><td><p>29%</p></td><td colspan="2"><p>17%</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="3"><p>Hazard ratio 0.58, CI<sub>95%</sub> 0.43; 0.73, p&lt;0.001</p></td></tr><tr><td><p>Proportion progressed<sup>1</sup>(24-week confirmation)</p></td><td><p>23%</p></td><td colspan="2"><p>11%</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="3"><p>Hazard ratio 0.46, CI<sub>95% </sub>0.33; 0.64, p&lt;0.001</p></td></tr><tr><td><p>MRI (0-2 years)</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Median % change in T2-hyperintense lesion volume</p></td><td><p>+8.8%</p></td><td colspan="2"><p>-9.4%</p><p>(p&lt;0.001)</p></td></tr><tr><td><p>Mean number of new or newly-enlarging T2‑hyperintense lesions</p></td><td><p>11.0</p></td><td colspan="2"><p>1.9</p><p>(p&lt;0.001)</p></td></tr><tr><td><p>Mean number of T1-hypointense lesions</p></td><td><p>4.6</p></td><td colspan="2"><p>1.1</p><p>(p&lt;0.001)</p></td></tr><tr><td><p>Mean number of Gd-enhancing lesions</p></td><td><p>1.2</p></td><td colspan="2"><p>0.1</p><p>(p&lt;0.001)</p></td></tr><tr><td colspan="4"><p><sup>1 </sup>Progression of disability was defined as at least a 1.0 point increase on the EDSS from a baseline EDSS &gt;=1.0 sustained for 12 or 24 weeks or at least a 1.5 point increase on the EDSS from a baseline EDSS =0 sustained for 12 or 24 weeks.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>In the sub-group of patients indicated for treatment of rapidly evolving RRMS (patients with 2 or more relapses and 1 or more Gd+ lesion), the annualised relapse rate was 0.282 in the natalizumab-treated group (n&nbsp;=&nbsp;148) and 1.455 in the placebo group (n&nbsp;=&nbsp;61) (p&nbsp;&lt;0.001). Hazard ratio for disability progression was 0.36 (95% CI: 0.17, 0.76) p&nbsp;=&nbsp;0.008. These results were obtained from a <em>post hoc</em> analysis and should be interpreted cautiously. No information on the severity of the relapses before inclusion of patients in the study is available.</p><p>&nbsp;</p><p><em><u>Tysabri Observational Program (TOP)</u></em></p><p>&nbsp;</p><p>Interim analysis of results (as of May 2015) from the ongoing Tysabri Observational Program (TOP), a phase 4, multicentre, single-arm study (n =5,770) demonstrated that patients switching from beta interferon (n = 3,255) or glatiramer acetate (n = 1,384) to Tysabri showed a sustained, significant decrease in annualised relapse rate (p &lt; 0.0001). Mean EDSS scores remained stable over 5 years. Consistent with efficacy results observed for patients switching from beta interferon or glatiramer acetate to Tysabri, for patients switching from fingolimod (n = 147) to &nbsp;this medicinal product, a significant decrease in annualised relapse rate (ARR) was observed, which remained stable over 2 years, and mean EDSS scores remained similar from baseline to Year 2. The limited sample size and shorter duration of natalizumab exposure for this subgroup of patients should be considered when interpreting these data.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p><em><u>&nbsp;</u></em></p><p>A post-marketing meta-analysis was conducted using data from 621 paediatric MS patients treated with natalizumab (median age 17 years, range was 7 to 18 years, 91% aged &ge;14 years). Within this analysis, a limited subset of patients with data available prior to treatment (158 of the 621 patients) demonstrated a reduction in ARR from 1.466 (95% CI 1.337, 1.604) prior to treatment to 0.110 (95% CI 0.094, 0.128).</p><p>&nbsp;</p><p><em><u>Extended interval dosing</u></em></p><p><u>&nbsp;</u></p><p>In a pre-specified, retrospective analysis of US anti-JCV antibody positive Tysabri patients intravenously administered (TOUCH registry), the risk of PML was compared between patients treated with the approved dosing interval and patients treated with extended interval dosing as identified in the last 18 months of exposure (EID, average dosing intervals of approximately 6 weeks). The majority (85%) of patients dosed with EID had received the approved dosing for &ge;1 year prior to switching to EID. The analysis showed a lower risk of PML in patients treated with EID (hazard ratio = 0.06, 95% CI of hazard ratio = 0.01 to 0.22)..</p><p>&nbsp;</p><p>Efficacy has been modelled for patients who switch to longer dosing after &ge;1 year of approved dosing with this medicinal product under intravenous administration and who did not experience a relapse in the year prior to switching. Current pharmacokinetic/pharmacodynamic statistical modelling and simulation indicate that the risk of MS disease activity for patients switching to longer dosing intervals may be higher for patients with dosing intervals &ge;7 weeks. No prospective clinical studies have been completed to validate these findings.</p><p>&nbsp;</p><p>The efficacy of natalizumab when administered with EID has not been established; therefore, the benefit/risk balance of EID is unknown (see &ldquo;<em>Intravenous administration Q6W&rdquo;</em>).</p><p><em>&nbsp;</em></p><p><em>Intravenous administration Q6W</em></p><p><em>&nbsp;</em></p><p>Efficacy and safety were evaluated in a prospective, randomized, interventional, controlled, open-label, rater-blinded, international phase 3 study (NOVA, 101MS329), involving subjects with relapsing-remitting MS according to the 2017 McDonald criteria dosed intravenously every six weeks with natalizumab. The study was designed to estimate an efficacy difference between Q6W and Q4W dosing regimens.</p><p>&nbsp;</p><p>The study randomized 499 subjects aged 18-60, with an EDSS score &le;&nbsp;5.5 at screening, who received at least 1 year of natalizumab treatment IV Q4W and were clinically stable (no relapse in the last 12 months, no gadolinium (Gd) enhancing T1 lesions at screening). In the study, subjects who switched to Q6W after at least one year of IV Q4W treatment with natalizumab were evaluated in relation to subjects who continued on IV Q4W treatment.</p><p>&nbsp;</p><p>Baseline demographic subgroups of age, sex, duration of natalizumab exposure, country, body weight, anti-JCV status and number of relapses in the year prior to the first dose, number of relapses while on natalizumab, number of prior DMTs, and type of prior DMT were similar between the Q6W and Q4W dosing treatment arms.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:568px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 3.&nbsp; NOVA study: Main features and results</strong></p></td></tr><tr><td><p>Design</p></td><td colspan="2" style="vertical-align:top"><p>Monotherapy; phase 3b prospective, randomized, interventional, controlled, open-label, rater-blinded, international study</p></td></tr><tr><td style="vertical-align:top"><p>Subjects&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>RRMS (McDonald criteria)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment administration (part 1)</p></td><td style="vertical-align:top"><p>Natalizumab Q4W</p><p>300 mg I.V.</p></td><td style="vertical-align:top"><p>Natalizumab Q6W</p><p>300 mg I.V.</p></td></tr><tr><td style="vertical-align:top"><p>Randomized</p></td><td style="vertical-align:top"><p>248</p></td><td style="vertical-align:top"><p>251</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>RESULTS</p></td></tr><tr><td><p>mITT<sup>a</sup> population for part 1 at week 72</p></td><td><p>242</p></td><td><p>247</p></td></tr><tr><td><p>New/newly enlarging (N/NE) T2 lesions from baseline to Week 72</p><p>Subjects with number of lesions = 0</p></td><td style="vertical-align:bottom"><p>189 (78.1%)</p></td><td style="vertical-align:bottom"><p>202 (81.8%)</p></td></tr><tr><td><p>= 1</p></td><td><p>7 (3.6%)</p></td><td><p>5 (2.0%)</p></td></tr><tr><td><p>= 2</p></td><td><p>1 (0.5%)</p></td><td><p>2 (0.8%)</p></td></tr><tr><td><p>= 3</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>= 4</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>&ge; 5</p></td><td><p>0</p></td><td><p>2* (0.8%)</p></td></tr><tr><td><p>missing</p></td><td><p>45 (18.6%)</p></td><td><p>36 (14.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted mean N/NE T2-hyperintense lesions (primary endpoint)*</p><p>95% CI<sup>b,c</sup></p></td><td style="vertical-align:bottom"><p>0.05</p><p>(0.01, 0.22)</p></td><td style="vertical-align:bottom"><p>0.20</p><p>(0.07, 0.63)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p>p = 0.0755</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of subjects that developed N/NE T2 lesions</p></td><td><p>4.1%</p></td><td><p>4.3%</p></td></tr><tr><td><p>Proportion of subjects who developed T1-hypointense lesions</p></td><td><p>0.8%</p></td><td><p>1.2%</p></td></tr><tr><td><p>Proportion of subjects who developed Gd-enhancing lesions</p></td><td><p>0.4%</p></td><td><p>0.4%</p></td></tr><tr><td><p>Adjusted annualized relapse rate</p></td><td><p>0.00010</p></td><td><p>0.00013</p></td></tr><tr><td><p>Proportion of subjects free of relapse**</p></td><td><p>97.6%</p></td><td><p>96.9%</p></td></tr><tr><td><p>Proportion free of 24-week confirmed EDSS worsening</p></td><td><p>92%</p></td><td><p>90%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> mITT population, which included all randomized participants who received at least 1 dose of study treatment (natalizumab SID or natalizumab EID) and had at least 1 postbaseline result from the following clinical efficacy assessments: MRI efficacy assessments, relapses, EDSS, 9-HPT, T25FW, SDMT, TSQM, CGI scale.</p><p><sup>b </sup>Estimated using negative binomial regression with treatment as classification and baseline body weight (&le;&nbsp;80 vs &gt;&nbsp;80&nbsp; kg), duration of natalizumab exposure at baseline (&le;&nbsp;3 vs &gt;&nbsp;3 years), and region (North America, the UK, Europe and Israel, and Australia) as covariates.</p><p><sup>c </sup>Observed lesions are included for analysis regardless of intercurrent events, and missing values due to efficacy or safety (6 subjects switched to Q4W dosing and 1 subject each on Q6W and Q4W dosing discontinued treatment) are imputed by the worst case of subjects on treatment at the same visit in the same treatment group or otherwise via multiple imputation.</p><p>* The numerical difference seen in the N/NE lesions between the two treatment groups was driven by a high number of lesions occurring in two subjects in the Q6W arm &ndash; one subject who developed lesions three months after treatment discontinuation and a second subject who was diagnosed with &nbsp;asymptomatic PML at week 72.</p><p>** Relapses &ndash; clinical relapses were assessed as defined by new or recurrent neurologic symptoms not associated with fever or infection having a minimum duration of 24 hours.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following the repeat intravenous administration of a 300&nbsp;mg dose of natalizumab to MS patients, the mean maximum observed serum concentration was 110&nbsp;&plusmn;&nbsp;52&nbsp;&mu;g/mL. Mean average steady-state trough natalizumab concentrations over the dosing period ranged from 23&nbsp;&mu;g/mL to 29&nbsp;&mu;g/mL in Q4W dosing. At any time, mean trough concentrations for the Q6W regimen were approximately 60 to 70% lower than for the Q4W regimen. The predicted time to steady state was approximately 24&nbsp;weeks. Population pharmacokinetic analysis includes 12 studies and 1,781<strong>&nbsp;</strong>subjects receiving doses ranging from 1 to 6<strong>&nbsp;</strong>mg/kg and fixed doses of 150/300<strong>&nbsp;</strong>mg.</p><p><em>&nbsp;</em></p><p><u>Distribution </u></p><p><u>&nbsp;</u></p><p>Median steady-state volume of distribution was 5.96<strong>&nbsp;</strong>L (4.59-6.38<strong>&nbsp;</strong>L, 95% confidence interval).</p><p><strong>&nbsp;</strong></p><p><u>Elimination</u></p><p>&nbsp;</p><p>Population median estimate for linear clearance was 6.1<strong>&nbsp;</strong>mL/h (5.75-6.33<strong>&nbsp;</strong>mL/h, 95% confidence interval) and the estimated median half-life was 28.2<strong>&nbsp;</strong>days. The 95<sup>th</sup> percentile interval of the terminal half-life is from 11.6 to 46.2 days.</p><p>&nbsp;</p><p>The population analysis of 1,781<strong>&nbsp;</strong>patients explored the effects of selected covariates including body weight, age, gender, presence of anti-natalizumab antibodies and formulation on pharmacokinetics. Only body weight, the presence of anti-natalizumab antibodies and the formulation used in phase 2 studies were found to influence natalizumab disposition. Natalizumab clearance increased with body weight in a less-than-proportional manner, such that a +/-43% change in body weight resulted in only a -33% to 30% change in clearance. The presence of persistent anti-natalizumab antibodies increased natalizumab clearance approximately 2.45-fold, consistent with reduced serum natalizumab concentrations observed in persistently antibody-positive patients.</p><p>&nbsp;</p><p><u>Special Populations</u></p><p><u>&nbsp;</u></p><p><em><u>Paediatric population</u></em></p><p><em>&nbsp;</em></p><p>The pharmacokinetics of natalizumab in paediatric MS patients has not been established.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>&nbsp;</p><p>The pharmacokinetics of natalizumab in patients with renal insufficiency has not been studied.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>&nbsp;</p><p>The pharmacokinetics of natalizumab in patients with hepatic insufficiency has not been studied.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.</p><p>&nbsp;</p><p>Consistent with the pharmacological activity of natalizumab, altered trafficking of lymphocytes was seen as white blood cell increases as well as increased spleen weights in most <em>in vivo</em> studies. These changes were reversible and did not appear to have any adverse toxicological consequences.</p><p>&nbsp;</p><p>In studies conducted in mice, growth and metastasis of melanoma and lymphoblastic leukaemia tumour cells was not increased by the administration of natalizumab.</p><p>&nbsp;</p><p>No clastogenic or mutagenic effects of natalizumab were observed in the Ames or human chromosomal aberration assays. Natalizumab showed no effects on <em>in vitro</em> assays of &alpha;4‑integrin‑positive tumour line proliferation or cytotoxicity.</p><p>&nbsp;</p><p>Reductions in female guinea pig fertility were observed in one study at doses in excess of the human dose; natalizumab did not affect male fertility.</p><p>&nbsp;</p><p>The effect of natalizumab on reproduction was evaluated in 5 studies, 3 in guinea pigs and 2 in <em>cynomolgus</em> monkeys. These studies showed no evidence of teratogenic effects or effects on growth of offspring. In one study in guinea pigs, a small reduction in pup survival was noted. In a study in monkeys, the number of abortions was doubled in the natalizumab 30&nbsp;mg/kg treatment groups versus matching control groups. This was the result of a high incidence of abortions in treated groups in the first cohort that was not observed in the second cohort. No effects on abortion rates were noted in any other study. A study in pregnant <em>cynomolgus </em>monkeys demonstrated natalizumab‑related changes in the foetus that included mild anaemia, reduced platelet counts, increased spleen weights and reduced liver and thymus weights. These changes were associated with increased splenic extramedullary haematopoiesis, thymic atrophy and decreased hepatic haematopoiesis. Platelet counts were also reduced in offspring born to mothers treated with natalizumab until parturition, however there was no evidence of anaemia in these offspring. All changes were observed at doses in excess of the human dose and were reversed upon clearance of natalizumab.</p><p>&nbsp;</p><p>In <em>cynomolgus</em> monkeys treated with natalizumab until parturition, low levels of natalizumab were detected in the breast milk of some animals.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium phosphate, monobasic, monohydrate</p><p>Sodium phosphate, dibasic, heptahydrate</p><p>Sodium chloride</p><p>Polysorbate 80 (E 433)</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tysabri 300<strong>&nbsp;</strong>mg concentrate for solution for infusion must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial

4 years

Diluted solution

After dilution with sodium chloride 9 mg/mL (0.9%) solution for injection, immediate use is recommended. If not used immediately, the diluted solution must be stored at 2˚C to 8˚C and infused within 8 hours of dilution. In use storage times and conditions prior to use are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2˚C&nbsp;to&nbsp;8˚C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>15&nbsp;mL concentrate in a vial (type I glass) with a stopper (chlorobutyl rubber) and a seal (aluminium) with a flip‑off cap.</p><p>&nbsp;</p><p>Pack size of one vial per carton.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Instructions for use:</p><p>&middot;&nbsp;&nbsp; Inspect the vial for particles prior to dilution and administration. If particles are observed and/or the liquid in the vial is not colourless, clear to slightly opalescent, the vial must not be used.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Use aseptic technique when preparing the solution for intravenous (IV) infusion. Remove flip‑off cap from the vial. Insert the syringe needle into the vial through the centre of the rubber stopper and remove 15&nbsp;mL concentrate for solution for infusion.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Add the 15&nbsp;mL concentrate for solution for infusion to 100&nbsp;mL sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection. Gently invert the solution to mix completely. Do not shake.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; This medicinal product must not be mixed with other medicinal products or diluents.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Visually inspect the diluted medicinal product for particles or discolouration prior to administration. Do not use if it is discoloured or if foreign particles are seen.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; The diluted medicinal product is to be used as soon as possible and within 8&nbsp;hours of dilution. If the diluted medicinal product is stored at 2˚C&nbsp;to&nbsp;8˚C (do not freeze), allow the solution to warm to room temperature prior to infusion.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; The diluted solution is to be infused intravenously over 1&nbsp;hour at a rate of approximately 2&nbsp;mL per minute.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; After the infusion is complete, flush the intravenous line with sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Each vial is for single&ndash;use only.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                  May 2022

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>